Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 03 2024
0mins
Source: Newsfilter
Asahi Kasei's Acquisition of Calliditas: Asahi Kasei Corporation has acquired over 90% of Calliditas Therapeutics AB and plans to initiate compulsory redemption of the remaining shares, leading to corporate actions including delisting from Nasdaq Stockholm and the Nasdaq Global Select Market.
Extraordinary General Meeting Announcement: Calliditas' Board of Directors has scheduled an Extraordinary General Meeting for September 30, 2024, at Asahi Kasei's request, to elect a new Board of Directors amidst these changes.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
